Articles from Frazier Life Sciences

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Gordon Empey as Chief Operating Officer (COO). Gordon, who brings more than 25 years of experience advising venture capital investors and life sciences companies, will continue in his roles as Partner and General Counsel alongside his new responsibilities as COO.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced that Chris Aakre, Ph.D., is joining the FLS team as Principal of Company Creation. Dr. Aakre brings close to 10 years of providing strategic guidance in the life sciences space.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the promotion of Anna Chen, Ph.D., to Partner.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Gerald (Jerry) Nepom, M.D., Ph.D., as Senior Advisor.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of James Li, M.D., as a Venture Partner.

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors.

Frazier Life Sciences (FLS), a longstanding healthcare investment firm focused on innovative therapeutics, today announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscribed fundraise.

Frazier Life Sciences (FLS), a longstanding investment firm investing in innovative biopharmaceuticals, today announced the addition of industry veteran Adam Simpson as Venture Partner in its Company Creation team.

Frazier Life Sciences announced the addition of Bryan A. Irving, Ph.D. as a Senior Advisor. He has 30 years of experience as a T cell immunologist, including 23 years in the biotech industry focused on discovering and progressing immune drug candidates into the clinic for both autoimmune and oncology indications.

Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.

Frazier Life Sciences announced the addition of Annette Doherty, Ph.D., OBE, FRSC as a Senior Advisor. She has 35 years of international experience as a chemist and leader of pharmaceutical research and development divisions and has been directly involved in leading the development and launch of over 30 new medicines in a range of therapeutic areas, including respiratory, infectious diseases, oncology and immunology.

Frazier Life Sciences announced the addition of Tao Fu as a Venture Partner. He has over 25 years of business development, general management, operations, strategy, and commercial leadership experience in the pharmaceutical and biotech industry.

Frazier Life Sciences announced today the closing of Frazier Life Sciences XI, L.P. (“FLS XI”), exceeding its target of $800 million and raising more than $987 million in capital commitments in an oversubscribed fundraise. FLS XI is Frazier Life Sciences’ fourth venture fund focused on biopharmaceuticals and represents a continuation of the team’s investment strategy of advancing innovative therapeutics through company creation, early-stage venture (Series A and Series B), and crossover and public investing.

Frazier Life Sciences announced the addition of Angie You, Ph.D. as a Senior Advisor. She most recently served as Chief Executive Officer of Amunix Pharmaceuticals Inc. until its acquisition by Sanofi for up to $1.225 billion.